Article Sidebar

PDF
Date Published: 17/10/2022
Abstract Views: 203
Views PDF: 108
DOI: https://doi.org/10.51298/vmj.v519i1.3547
Issue
Vol. 519 No. 1 (2022)
Section
Các bài báo
How to Cite
Thị Thái Hoà, N. ., Thế Cường, T. ., & Mai Lan, N. . (2022). INITIAL RESULTS OF CHEMORADIATION THERAPY FOR STAGE III ADENOCARCINOMA NON – SMALL CELL LUNG CANCER BY CISPLATIN COMBINE WITH ETOPOSIDE OR PEMETREXED REGIMENT. Vietnam Medical Journal, 519(1). https://doi.org/10.51298/vmj.v519i1.3547

INITIAL RESULTS OF CHEMORADIATION THERAPY FOR STAGE III ADENOCARCINOMA NON – SMALL CELL LUNG CANCER BY CISPLATIN COMBINE WITH ETOPOSIDE OR PEMETREXED REGIMENT

Nguyễn Thị Thái Hoà1,, Trịnh Thế Cường2, Nguyễn Mai Lan3
1 Vietnam National Cancer Hospital
2 E Hospital
3 Hanoi Medical University

Main Article Content

Abstract

Stage III non-small cell lung cancer, the basic treatment is chemotherapy and radiation. Chemotherapy regimens commonly used in combination with radiotherapy are platinum-based regimens. Objectives: To evaluate the response rate of 2 regimens Etoposide – Cisplatin (EP) and Pemetrexed – Cisplatin (PeC) concomitantly with radiation for stage III lung adenocarcinoma. Subjects and methods: A retrospective study evaluated the response rates of 50 patients treated with Etoposide - Cisplatin (EP) regimen and 31 patients treated with Pemetrexed - Cisplatin (PeC) regimen concurrently with 3D radiation for inoperable stage III lung adenocarcinoma. Results: The response rate of EP chemotherapy was 68%; PemC regimen was 54.8%. Stage IIIA-B and IIIC response to PeC regimen were 71.4% and 20%; EP regimens are 72.5% and 50%. Response to PeC regimen, age group above and below 60 was 57% and EP regimen responded 57% and 53%, respectively. Conclusion: The response rate was not statistically significant between the 2 chemotherapy regimens

Article Details

Keywords

Non-small cell lung cancer, concurrent chemoradiotherapy, chemotherapy regimens

References

1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-2190. doi:10.1200/JCO.2009.26.2543
2. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr325
3. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28(4):777-783. doi:10.1093/annonc/mdx009
4. Senan S, Brade A, Wang L, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer. J Clin Oncol. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.8824
5. Trần Mai Phương. Đánh giá kết quả hóa xạ trị đồng thời ungthư phổi không tế bào nhỏ giai đoạn IIIB tại bệnh viện K. Luận văn tốt nghiệp Bác sỹ nội trú.Trường Đại học Y Hà Nội.2009.
6. Wang L, Wu YL, Lu S, et all. An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. Asia Pac J Clin Oncol. 2016 Dec;12(4):380-387. doi: 10.1111/ ajco.12513. Epub 2016 Jun 17.PMID: 27312514